Vaccine Contract Manufacturing Market Report by Vaccine Type (Attenuated, Inactivated, Subunit-based, Toxoid-based, DNA-based), Workflow (Downstream, Upstream), Application (Human Use, Veterinary), and Region 2024-2032
세계의 백신 수탁 제조 시장 규모는 2023년 28억 달러에 달했습니다. 앞으로 IMARC Group은 예측 기간 동안 8.8%의 복합 연간 성장률(CAGR)을 보일 전망이며 2032년에는 61억 달러에 달할 것으로 예측했습니다.
백신 수탁 제조는 백신의 대량 생산을 제조 위탁 기관(CMO)에 위탁하는 것입니다. 이러한 조직은 사전 포뮬레이션 업무, 제형 개발, 제법 개발, 안정성 시험, 전임상 활동, 등록 배치 및 상업 제조를 포함한 수많은 서비스를 제공합니다. 이 외에도 제약 회사의 생산 체인을 확장하기위한 전문 지식과 혁신적인 기술도 제공합니다. 현재 개발 비용 절감과 복잡한 제조 프로토콜을 이유로 백신 제조 업무의 아웃소싱에 대한 수요가 세계의적으로 높아지고 있습니다.
예방 접종은 동물뿐만 아니라 인간의 건강 증진에도 매우 중요한 역할을합니다. 항생제의 필요성을 줄이고 질병을 예방합니다. 예방 접종에 대한 의식이 증가하고 심각한 질병과 감염으로부터 보호하는 것과 같은 많은 관련 이점이 예방 접종 프로그램과 예방 접종에 대한 수요를 유발합니다. 이것은 제조에 필요한 자본의 복잡성을 이해하는 것과 함께 주요 제약 회사를 백신 제조의 아웃소싱으로 이끌고 있습니다. 이와는 별도로, 저자원국에서의 백신 제조를 위한 설비나 숙련 노동자의 부족도 세계의 백신 수탁 제조 시장의 성장에 기여하고 있습니다. 또한 EB66 및 GPEx와 같은 발현 시스템 및 세포 배양 배지 플랫폼의 채택을 포함한 기술의 발전이 시장 성장을 지원합니다. 또한, 많은 국가에서 코로나바이러스 감염(COVID-19)의 증례가 우려할 정도로 증가하고 있기 때문에 백신 개발 기업은 CMO와 아웃소싱 계약을 맺게 되었습니다. 이것은 시장 성장에 유리한 전망을 창출합니다.
이 보고서에서 다루는 주요 질문
- 세계의 백신 수탁 제조 시장은 지금까지 어떻게 추이하고 향후 어떻게 추이할 것인가?
- COVID-19는 세계의 백신 수탁 제조 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은?
- 백신 유형별 시장 분석은?
- 워크플로우별 시장 분석은?
- 용도별 시장 분석은?
- 업계의 밸류체인의 다양한 단계란?
- 업계의 주요 촉진요인과 도전은 무엇인가?
- 세계의 백신 수탁 제조 시장의 구조와 주요 진출기업은?
- 업계 경쟁도는?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사의 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 백신 수탁 제조 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 분석 : 백신 유형별
- 약독화
- 불활성화
- 서브 유닛 베이스
- 톡소이드 베이스
- DNA 베이스
제7장 시장 분석: 워크플로우별
- 하류
- 시장 동향
- 주요 부문
- 충전 및 마무리 작업
- 분석 및 품질관리 연구
- 포장
- 시장 예측
- 업스트림
- 시장 동향
- 주요 부문
- 포유류 발현 시스템
- 박테리아 발현 시스템
- 효모 발현 시스템
- 바큘로바이러스/곤충 발현 시스템
- 기타
- 시장 예측
제8장 시장 분석 : 용도별
제9장 시장 분석 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
- 개요
- 구매자의 협상력
- 공급기업의 협상력
- 경쟁도
- 신규 진입업자의 위협
- 대체품의 위협
제13장 가격 분석
제14장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 프로파일
- Ajinomoto Co. Inc.
- Albany Molecular Research Inc
- Catalent Inc
- Cobra Biologics Limited(Charles River Laboratories International Inc.)
- Cytovance Biologics Inc.(Hepalink USA Inc.)
- Fujifilm Holdings Corporation
- ICON plc
- IDT Biologika GmbH
- Lonza Group AG
- Merck KGaA
- Pharmaceutical Product Development LLC
- PRA Health Sciences Inc.
BJH
The global vaccine contract manufacturing market size reached US$ 2.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.1 Billion by 2032, exhibiting a growth rate (CAGR) of 8.8% during 2024-2032.
Vaccine contract manufacturing refers to the outsourcing of large-scale production of vaccines to contract manufacturing organizations (CMOs). These organizations offer numerous services, including pre-formulation work, formulation development, method development, stability studies, pre-clinical activities, registration batches and commercial manufacturing. Apart from this, they provide expertise and innovative technologies to expand the production chain of pharmaceutical companies. At present, the demand for outsourcing vaccine manufacturing activities is escalating worldwide on account of reduced development costs and complex production protocols.
Vaccination plays a pivotal role in improving human as well as veterinary health. It reduces the need for antibiotics and prevents diseases. The increasing awareness about vaccination and numerous associated benefits, such as protection from severe illnesses and infectious diseases, is catalyzing the demand for immunization programs and inoculations. This, in confluence with understanding the complexity of capital requirement for production, has led the leading pharmaceutical companies to outsource vaccine manufacturing. Apart from this, the lack of equipment and skilled labor for vaccine production in low-resource countries is also contributing to the global vaccine contract manufacturing market growth. Moreover, technological advancements, including the introduction of expression systems like the EB66 and GPEx and cell culture media platforms, are supporting the market growth. Furthermore, the alarmingly growing cases of coronavirus disease (COVID-19) in numerous countries have propelled the vaccine developers to sign outsourcing agreements with CMOs. This is creating a favorable outlook for the growth of the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global vaccine contract manufacturing market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on vaccine type, workflow and application.
Breakup by Vaccine Type:
Attenuated
Inactivated
Subunit-based
Toxoid-based
DNA-based
Breakup by Workflow:
Downstream
Fill and Finish Operations
Analytical and QC Studies
Packaging
Upstream
Mammalian Expression Systems
Bacterial Expression Systems
Yeast Expression Systems
Baculovirus/Insect Expression Systems
Others
Breakup by Application:
Human Use
Veterinary
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Ajinomoto Co. Inc., Albany Molecular Research Inc, Catalent Inc, Cobra Biologics Limited (Charles River Laboratories International Inc.), Cytovance Biologics Inc. (Hepalink USA Inc.), Fujifilm Holdings Corporation, ICON plc, IDT Biologika GmbH, Lonza Group AG, Merck KGaA, Pharmaceutical Product Development LLC and PRA Health Sciences Inc.
Key Questions Answered in This Report:
- How has the global vaccine contract manufacturing market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global vaccine contract manufacturing market?
- What are the key regional markets?
- What is the breakup of the market based on the vaccine type?
- What is the breakup of the market based on the workflow?
- What is the breakup of the market based on the application?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global vaccine contract manufacturing market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Vaccine Contract Manufacturing Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Vaccine Type
- 6.1 Attenuated
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Inactivated
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Subunit-based
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Toxoid-based
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 DNA-based
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
7 Market Breakup by Workflow
- 7.1 Downstream
- 7.1.1 Market Trends
- 7.1.2 Key Segments
- 7.1.2.1 Fill and Finish Operations
- 7.1.2.2 Analytical and QC studies
- 7.1.2.3 Packaging
- 7.1.3 Market Forecast
- 7.2 Upstream
- 7.2.1 Market Trends
- 7.2.2 Key Segments
- 7.2.2.1 Mammalian Expression Systems
- 7.2.2.2 Bacterial Expression Systems
- 7.2.2.3 Yeast Expression Systems
- 7.2.2.4 Baculovirus/Insect Expression Systems
- 7.2.2.5 Others
- 7.2.3 Market Forecast
8 Market Breakup by Application
- 8.1 Human Use
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Veterinary
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Ajinomoto Co. Inc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Albany Molecular Research Inc
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 SWOT Analysis
- 14.3.3 Catalent Inc
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Cobra Biologics Limited (Charles River Laboratories International Inc.)
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.5 Cytovance Biologics Inc. (Hepalink USA Inc.)
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.6 Fujifilm Holdings Corporation
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 ICON plc
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 IDT Biologika GmbH
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.9 Lonza Group AG
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Merck KGaA
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.11 Pharmaceutical Product Development LLC
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.11.4 SWOT Analysis
- 14.3.12 PRA Health Sciences Inc.
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio
- 14.3.12.3 Financials
